Key result
Anti-cancer immunotherapies are associated with rare but potentially severe cardiotoxicities, necessitating comprehensive cardiovascular assessments and routine biomarker monitoring for early detection.
Why the study?
Anti-cancer immunotherapies are associated with rare but potentially severe cardiotoxicities, necessitating a call for stronger evidence-based guidelines to manage and prevent these cardiovascular complications.
This review emphasizes the necessity of baseline cardiovascular risk stratification and routine monitoring to mitigate rare but severe cardiotoxicities associated with anti-cancer immunotherapies.
May warrant cardio-oncology vigilance with immunotherapies; leaves open optimal monitoring strategies pending prospective trials.
Anti-cancer immunotherapies, particularly immune checkpoint inhibitors, have significantly advanced oncology treatments but are associated with rare, potentially severe cardiotoxicities. Despite their success, these therapies are associated with immune-related adverse events including rare but severe immunotherapy-related cardiotoxicities. This review examines various immunotherapy types, such as immune checkpoint inhibitors, adoptive T-cell therapies, and cancer vaccines, highlighting their cardiovascular risks. Cardiotoxicities can lead to life-threatening complications, especially in high-risk patients. Early detection and prevention are crucial, with comprehensive cardiovascular assessments and routine biomarker monitoring playing a central role. With immunotherapies becoming more prevalent, this review calls for stronger evidence-based guidelines to manage and prevent these cardiovascular complications, ensuring that patients can benefit from life-saving immunotherapies without jeopardizing cardiovascular health.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2025) conducted a review in Anti-cancer immunotherapy-related cardiotoxicity. Anti-cancer immunotherapies was evaluated. Anti-cancer immunotherapies are associated with rare but potentially severe cardiotoxicities, necessitating comprehensive cardiovascular assessments and routine biomarker monitoring for early detection.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: